Safety and tolerability of bosentan in the management of pulmonary arterial hypertension
Kari E Roberts, Ioana R PrestonPulmonary, Critical Care and Sleep Medicine, Tufts Medical Center, Boston, Massachusetts, USAAbstract: Endothelin receptor antagonism has emerged as an important therapeutic approach in pulmonary arterial hypertension (PAH). Bench to bedside scientific research has cle...
Main Authors: | Kari E Roberts, Ioana R Preston |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-03-01
|
Series: | Drug Design, Development and Therapy |
Online Access: | http://www.dovepress.com/safety-and-tolerability-of-bosentan-in-the-management-of-pulmonary-art-a3007 |
Similar Items
-
Review of bosentan in the management of pulmonary arterial hypertension
by: Eli Gabbay, et al.
Published: (2008-01-01) -
Bosentan use in pulmonary arterial hypertension: Russian and foreign experience
by: Z S Valieva, et al.
Published: (2017-08-01) -
Evaluation of effectiveness and safety of the first Russian-manufactured generic bosentan use in patients with pulmonary arterial hypertension
by: O A Arkhipova, et al.
Published: (2018-12-01) -
Bosentan for Treatment of Pediatric Idiopathic Pulmonary Arterial Hypertension: State-of-the-Art
by: Yuchen Wang, et al.
Published: (2019-07-01) -
Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient
by: Christopher J Valerio, et al.
Published: (2009-08-01)